Scribe expects to initiate a first-in-human hypercholesterolemia study in mid-2026 with STX-1150, its lead cardiometabolic ...
The last time I wrote about Verve Therapeutics (VERV), it was in a Seeking Alpha article entitled "Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts." With ...
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics (VERV), a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of ...
One of the main goals in the prevention of cardiovascular disorders is to maintain low-density lipoprotein cholesterol (LDL-C) at consistently low levels to ensure long-term cardiovascular protection.
When mice are engineered to carry a variant of the human PCSK9 gene, they experience higher rates of breast cancer metastasis, as is apparent in these images of mouse lung tissue showing PCSK9’s ...
Eli Lilly to buy Verve Therapeutics for $10.50 per share, with total potential payout up to $13.50 per share. The $1.3 billion deal offers a 113% premium to Verve’s 30-day average stock price. The ...
A preclinical study presented at the 32nd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), held in Seville Oct. 7-10, showed a new epigenetic editing technology that enables ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results